Literature DB >> 9430183

Outcomes assessment in the NCCN.

J C Weeks1.   

Abstract

Outcomes assessment has two primary goals: the evaluation of treatments and the evaluation of quality of care. Data on the outcomes associated with specific interventions may provide an empiric basis for guidelines in areas for which no randomized trial data are available. Also, monitoring of patterns of care and outcomes is an essential component of institutional efforts to implement guidelines and to benchmark themselves against regional and national norms. The National Comprehensive Cancer Network (NCCN) has adopted a three-phase approach to its outcomes assessment program. Phase 1, already completed, involved taking a systematic inventory of members' existing institutional data sources. Phase 2, which is currently in progress, entails pooling data from existing outcomes data bases. In particular, tumor registry data from the National Cancer Data Base are being used to examine patterns of care and outcomes in NCCN institutions and to benchmark them against national norms. Phase 3, begun within the past year, involves the creation of a uniform outcomes assessment system for the NCCN.

Entities:  

Mesh:

Year:  1997        PMID: 9430183

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  16 in total

1.  A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network.

Authors:  Caprice K Christian; Joyce Niland; Stephen B Edge; Rebecca A Ottesen; Melissa E Hughes; Richard Theriault; John Wilson; Charles A Hergrueter; Jane C Weeks
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Outcome as a measure of quality of care in oncology: experience at sultan qaboos university hospital, oman.

Authors:  Ikram A Burney; Mansour S Al Moundhri; Azhar J Rizvi; Shyam S Ganguly; Rashid Al Abri; Rafi A Ashrafi
Journal:  Sultan Qaboos Univ Med J       Date:  2008-03

3.  Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?

Authors:  Yu-Ning Wong; Rebecca A Ottesen; Melissa E Hughes; Joyce C Niland; Richard Theriault; Stephen B Edge; Douglas Blayney; Jane C Weeks
Journal:  Oncologist       Date:  2011-03-30

4.  The effect of age on delay in diagnosis and stage of breast cancer.

Authors:  Ann H Partridge; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Rulla M Tamimi
Journal:  Oncologist       Date:  2012-05-03

5.  Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.

Authors:  Rachel A Freedman; Melissa E Hughes; Rebecca A Ottesen; Jane C Weeks; Yulei He; Yu-Ning Wong; Richard Theriault; Nancy L Keating
Journal:  Cancer       Date:  2012-09-25       Impact factor: 6.860

6.  Time to diagnosis and breast cancer stage by race/ethnicity.

Authors:  Erica T Warner; Rulla M Tamimi; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Ann H Partridge
Journal:  Breast Cancer Res Treat       Date:  2012-10-26       Impact factor: 4.872

7.  Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.

Authors:  Michael J Hassett; Melissa E Hughes; Joyce C Niland; Stephen B Edge; Richard L Theriault; Yu-Ning Wong; John Wilson; W Bradford Carter; Douglas W Blayney; Jane C Weeks
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

8.  Selecting high priority quality measures for breast cancer quality improvement.

Authors:  Michael J Hassett; Melissa E Hughes; Joyce C Niland; Rebecca Ottesen; Stephen B Edge; Michael A Bookman; Robert W Carlson; Richard L Theriault; Jane C Weeks
Journal:  Med Care       Date:  2008-08       Impact factor: 2.983

9.  Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.

Authors:  Jennifer M Matro; Tianyu Li; Massimo Cristofanilli; Melissa E Hughes; Rebecca A Ottesen; Jane C Weeks; Yu-Ning Wong
Journal:  Clin Breast Cancer       Date:  2014-06-23       Impact factor: 3.225

10.  Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network.

Authors:  Rinaa S Punglia; Melissa E Hughes; Stephen B Edge; Richard L Theriault; Michael A Bookman; John L Wilson; Rebecca A Ottesen; Joyce C Niland; Jane C Weeks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-28       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.